- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SANOFI INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Aventis Pharma Quarterly Results 
(HOCM)
Here are the latest quarterly results of Aventis Pharma. For more details, see the Aventis Pharma financial fact sheet and Aventis Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Aventis Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-16 |
3
Sep-16 |
3
Mar-17 |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 6,080 | 6,242 | 5,529 | 6,006 | 6,675 | 6,704 | 6,177 | 6,836 | |
| Other income | Rs m | 164 | 148 | 159 | 284 | 208 | 182 | 226 | 208 | |
| Turnover | Rs m | 6,244 | 6,390 | 5,688 | 6,290 | 6,883 | 6,886 | 6,403 | 7,044 | |
| Expenses | Rs m | 4,622 | 4,795 | 4,514 | 4,852 | 4,838 | 5,360 | 4,833 | 5,191 | |
| Gross profit | Rs m | 1,458 | 1,447 | 1,015 | 1,154 | 1,837 | 1,344 | 1,344 | 1,645 | |
| Depreciation | Rs m | 300 | 300 | 253 | 255 | 257 | 257 | 254 | 254 | |
| Interest | Rs m | 7 | 3 | 4 | 0 | 0 | 11 | 0 | 0 | |
| Profit before tax | Rs m | 1,315 | 1,292 | 917 | 1,183 | 1,788 | 1,258 | 1,316 | 1,599 | |
| Tax | Rs m | 462 | 486 | 317 | 446 | 625 | 498 | 491 | 603 | |
| Profit after tax | Rs m | 853 | 806 | 600 | 737 | 1,163 | 760 | 825 | 996 | |
| Gross profit margin | % | 24.0 | 23.2 | 18.4 | 19.2 | 27.5 | 20.0 | 21.8 | 24.1 | |
| Effective tax rate | % | 35.1 | 37.6 | 34.6 | 37.7 | 35.0 | 39.6 | 37.3 | 37.7 | |
| Net profit margin | % | 14.0 | 12.9 | 10.9 | 12.3 | 17.4 | 11.3 | 13.4 | 14.6 | |
| Diluted EPS | Rs | 37.0 | 35.0 | 26.1 | 32.0 | 50.5 | 33.0 | 35.8 | 43.2 | |
| Diluted EPS (TTM) | Rs | 126.3 | 129.8 | 133.1 | 130.1 | 143.6 | 141.6 | 151.3 | 162.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Aventis Pharma 1QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: INDRAPRASTHA MEDICAL FULFORD INDIA BIOCON LTD NATCO PHARMA FRESENIUS KABI ONCO.
Compare SANOFI INDIA With: INDRAPRASTHA MEDICAL FULFORD INDIA BIOCON LTD NATCO PHARMA FRESENIUS KABI ONCO.
Compare SANOFI INDIA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)
Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.
Views on news
SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)
Aug 1, 2018Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.
How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)
Aug 3, 2018In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.
Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)
Aug 3, 2018To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?
NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)
Aug 1, 2018PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.
Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)
Aug 2, 2018Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.
More|
| |
SANOFI INDIA SHARE PRICE
Aug 14, 2018 (Close)
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA - DR. DATSONS LABS COMPARISON
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.